About Golden Helix

Webcast Recap: Evaluation of CNVs with VSClinical’s New ACMG Guideline Workflow

Nov 10, 2020

In the webcast, Evaluation of Copy Number Variants with VSClinical’s New ACMG Guideline Workflow, we discussed how VSClinical implements Section 4 of the ACMG guidelines. Specifically, we focused on integrating literature and publications to assess the pathogenicity of a CNV event when there was a lack of dosage sensitivity information.…

Read more →

Golden Helix’s Virtual 2020 Conference Booth

Oct 27, 2020

In lieu of conferences making the absolutely necessary decision to cancel this year’s conference, we created our Virtual 2020 Conference Booth! Even though it will never compare to the real deal, we hope you enjoy this blog post containing a few events we had planned this year. To start, let…

Read more →

Golden Helix’s NGS-Solutions for Clinical Variant Analysis: VSWarehouse

Aug 27, 2020

We have now reached the final blog of the NGS-Solutions for Clinical Variant Analysis series. Part I of this series explored the capture of variant classifications in the VSClinical environment when following the ACMG and AMP guidelines. Part II was similar in content but for the capture of clinically relevant…

Read more →

Golden Helix gets full marks in ClinGen’s list of Genomic Analysis Software Platforms

Aug 26, 2020

The potential of genetic testing to impact a patient’s life has been greatly accelerated by the sharing of variant interpretations done by clinical labs in public repositories such as ClinVar. This is not an inevitable outcome, but the persistent work and advocacy of people like Dr. Heidi Rehm and organizations…

Read more →

WT1 Mutations: Side-by-Side Germline and Somatic Variant Evaluation in VSClinical

Jul 28, 2020

It is common knowledge that variants can be germline or somatic depending on whether the variant was inherited or acquired after birth. A well-known example is cancer-causing mutations in the BRCA genes, wherein the mutation may or may not have been inherited. Understanding the origin of the cancer-causing mutation is…

Read more →

Featured in The European Journal of Clinical and Biomedical Sciences: Investigating COVID-19 Infections Leveraging Next-Gen Sequencing

Jul 8, 2020

It is an honor to be published in the European Journal of Clinical and Biomedical Sciences (Volume 6, Issue 4) in an article co-authored by Dr. Christiane Scherer and myself, “Investigating the Global Spread of SARS-CoV-2 Leveraging Next-Gen Sequencing and Principal Component Analysis.” This study highlights how genomic surveillance of COVID-19…

Read more →

Coping Mechanisms in the COVID-19 World

Jun 4, 2020

Like many of you, I was supposed to attend the 2020 ACMG Meeting in San Antonio this March with a few colleagues. In addition to attending the conference, my first blog post for Golden Helix was going to be about our time at the conference. Thanks to the world-wide COVID-19…

Read more →

An Open Letter to Our Community

Jun 3, 2020

Dear All, Going back in time to the beginning of this year, it would have been difficult to imagine what our world would look like as of June 2020. Things changed quickly. While we are still in the midst of the COVID-19 pandemic, the senseless killing of George Floyd triggered…

Read more →

Genome Wide Association Tests and Mixed Linear Models in SVS

May 19, 2020

SVS offers several options to conduct genome wide association tests and mixed linear models. At times, it can be challenging to decide which test, model, or adjustments to use when setting up your analysis. I want to briefly explore the options available in SVS for association tests, and mixed linear…

Read more →

Webcast Recap: Using VarSeq Templates to Advance and Customize Variant Analysis

Apr 9, 2020

Thank you to everyone who joined me for yesterday’s webcast, Using VarSeq Templates to Advance and Customize Variant Analysis, I hope you all enjoyed it. If you missed the live event and are interested in knowing what we talked about, good news, you can watch the recorded version right here!…

Read more →

Webcast Recap: Drugs & Trials for Cancer Diagnostics

Mar 5, 2020

Introducing Drugs & Trials for Cancer Diagnostics VSClinical offers enormous simplicity and consistency in evaluating biomarkers and providing treatment options. Last month, we announced our newest feature to now include the automated collection of relevant clinical trials. The new capability was unveiled in our “Introducing Drugs & Trials for Cancer…

Read more →

Powerful Cohort Analysis with VarSeq’s Count Alleles Algorithm

Feb 25, 2020

Although VarSeq is intentionally designed to be a clinical NGS pipeline tool able to run a handful or even single samples through, we have many users who run large cohort style studies with the tool as well. One common use is to compare case/control data to isolate variants shared among…

Read more →

What to expect from Golden Helix in 2020!

Jan 3, 2020

Happy New Year! Certainly, I hope you had a relaxing time over the holidays with family and friends as well as a great start into the new year. 2019 was a real landmark year for Golden Helix. Please let me mention a few highlights: Now, for 2020 we will plan…

Read more →

Golden Helix’s End-to-End Architecture for Clinical Testing Labs

Dec 19, 2019

As clinical genetic tests have been adopted as a critical enabler of precision medicine, the number of tests offered by clinical labs and the volume of tested patients has grown by orders of magnitude in the past five years. The Gene Testing Registry, managed by the NIH, documented a rise…

Read more →

Somatic Variant Calling with Sentieon: Customizations

Dec 10, 2019

The first two blogs in this series covered Sentieon’s somatic variant calling from Tumor with Normal (Part I) and Tumor without Normal (Part II). In addition to providing multiple somatic variant calling processes, users also have access to high-sensitivity scripts and full support for the GRCh38 reference assembly. Without going…

Read more →

Somatic Variant Calling with Sentieon: Tumor-Only Workflow

Nov 19, 2019

To recap what we have covered in this blog series thus far, Sentieon allows users to call somatic variants against a matched normal sample and a tumor-only analysis. Part I of this series covered the variant calling workflow for tumors with matching normal samples. However, a common situation would be…

Read more →

Somatic Variant Calling with Sentieon: Tumor-Normal Workflow

Oct 31, 2019

As I mentioned in the first part of this series, Sentieon allows users to call somatic variants against a matched normal sample and a tumor-only analysis. Utilization of a Tumor-Normal Workflow In addition to the fundamental process of alignment and variant calling, there are a few more steps that will…

Read more →

What to expect from Golden Helix in 2019!

Jan 3, 2019

Happy New Year. I trust you had a relaxing time over the holidays with family and friends as well as a great start into 2019. Golden Helix certainly had a landmark year. There were many highlights that actually shaped the direction for us in the years to come. Please let…

Read more →

Our Philosophy on Quality in Product Testing and Development

Dec 6, 2018

High product quality is a foundational characteristic of a useful and successful product. Quality testing, therefore, is a necessary, albeit an open-ended task. It can at times seem a limitless undertaking in the present using experience from the past to improve the future. Nonetheless, it is approached as a development…

Read more →

Golden Helix Receives NIH-SBIR Phase 2 Grant 2R44 GM125432-02

Sep 24, 2018

It is our distinct pleasure to inform the GHI community that we have been awarded a Phase II SBIR Grant from the National Institutes of Health. As we are also preparing to celebrate our 20th Anniversary, these two events invoke a lot of excitement within our company and what lies…

Read more →